PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

18 May 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

15 May 2023 07:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

04 May 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

27 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

24 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

03 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 

29 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

28 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

16 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference

07 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

01 Mar 2023 08:00:02 By Nasdaq GlobeNewswire

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

27 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

16 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

08 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Participation in the Channelchek Takeaway Series

26 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

13 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

28 Dec 2022 08:00:00 By Nasdaq GlobeNewswire